

For the use only of a Registered Veterinary Practitioner or a Hospital or a Laboratory or a Farm.

Maropitant Citrate Tablets

PetOmitic™ -16/24/60 Yum-Tab!

For oral use in Dogs only
AntiEmetic

COMPOSITION:

Each uncoated tablet contains:
Maropitant Citrate Monohydrate Equivalent to Maropitant...16 mg / 24 mg / 60 mg
Excipients.....q.s.

INDICATIONS:

- For the prevention of nausea induced by chemotherapy.
- For the prevention of vomiting induced by motion sickness.

DOSAGE AND ADMINISTRATION:

For oral use:

For motion sickness, a light meal or snack before dosing is recommended; prolonged fasting before administration should be avoided. However, Maropitant tablets should not be administered wrapped or encapsulated in food as this may delay dissolution of the tablet and consequently the onset of efficacy.

Dogs should be carefully observed following administration to ensure that each tablet is swallowed.

For the prevention of nausea induced by chemotherapy and treatment and prevention of vomiting (except motion sickness), (only for dogs 8 weeks of age or older).

To treat or prevent vomiting, tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below.

To prevent vomiting, tablets should be given more than 1 hour in advance. The duration of the effect is approximately 24 hours and, therefore, tablets can be given the night before administration of an agent that may cause emesis (e.g. chemotherapy).

Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness)			
Dog body weight (kg)	Number of tablets		
	16 mg	24 mg	60 mg
3.0-4.0*	½		
4.1-8.0	1		
8.1-12.0		1	
12.1-24.0		2	
24.1-30.0			1
30.1-60.0			2

* Correct dose for dogs of less than 3 kg cannot be accurately achieved.

For prevention of vomiting induced by motion sickness, (only for dogs 16 weeks of age or older)

To prevent vomiting induced by motion sickness, Maropitant tablets should be administered once daily, at a dose of 8 mg maropitant per kg bodyweight, using the numbers of tablets given in the table below. Tablets should be administered at least one hour before starting the journey. The anti-emetic effect persists for at least 12 hours, which for convenience may allow administration the night before early morning travel. Treatment may be repeated for a maximum of two consecutive days.

Prevention of motion sickness			
Dog body weight (kg)	Number of tablets		
	16 mg	24 mg	60 mg
1.0-1.5		½	
1.6-2.0	1		
2.1-3.0		1	
3.1-4.0	2		
4.1-6.0		2	
6.1-7.5			1
7.6-10.0			2
10.1-15.0			2

TARGET SPECIES: Dogs

PHARMACODYNAMIC PROPERTIES: Pharmacotherapeutic group: Antiemetics.

ATC Vet Code: QAO4AD90.

PHARMACODYNAMICS:

Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family. Substance P is found in significant concentrations in the nuclei comprising the emetic centre and is considered the key neurotransmitter involved in vomiting. By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting.

PHARMACOKINETICS:

The pharmacokinetic profile of maropitant when administered as a single oral dose of 2 mg/kg body weight to dogs was characterised by a maximum concentration (C_{max}) in plasma of approximately 81 ng/ml; this was achieved within 1.9 hours post-dosing (T_{max}). Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t_{0.5}) of 4.03 hours. At a dose of 8 mg/kg, C_{max} of 776 ng/ml was reached at 1.7 hours post-dosing. The elimination half-life at 8 mg/kg was 5.47 hours.

WARNING & PRECAUTION:

- Do not exceed the recommended dosage.
- Wash hands after use.
- Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed.
- Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease.
- Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures, such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
- The safety of the veterinary medicinal product has not been established in dogs less than 16 weeks of age for the 8 mg/kg dose (motion sickness), and in dogs less than 8 weeks of age for the 2 mg/kg dose (vomiting) as well as in pregnant or lactating bitches. Use only according to the benefit-risk assessment by the responsible veterinarian.

CONTRAINDICATIONS: None.

ADVERSE EFFECTS:

Incidents of pre-travel vomiting, usually within two hours post-dosing were commonly reported after administration of the 8 mg/kg dose.

OVERDOSE:

Maropitant tablets were well tolerated when administered for 15 days at dosages up to 10 mg/kg bodyweight per day. Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been administered at doses in excess of 20 mg/kg.

STORAGE: Store below 30°C in a dry place.

PRESENTATION:

1 Blister containing 4 Tablets is packed in a Carton along with the Pack Insert.

**VETERINARY.
NOT FOR HUMAN USE.
FOR ANIMAL TREATMENT ONLY.**

KEEP OUT OF REACH OF CHILDREN & PETS, AWAY FROM FOOD.

Carefully read the accompanying instructions before use.

Veko®

Manufactured & Marketed by:

VEKO CARE PVT. LTD.

Plot No. E - 48 & 49, MIDC Ranjangaon, District - Pune, Maharashtra, INDIA. Pin Code : 412220.

Customer care: care@vekocare.com

TM : Trade Mark of Veko Care

VPP1E180

